Open Access
Subscription or Fee Access
IN SILICO EVALUATION OF INHIBITORY POTENTIAL OF SOME COMMERCIALLY AVAILABLE FLAVONOIDS AGAINST BETA- SECRETASE IN THE MANAGEMENT OF ALZHIEMER’S DISEASE
Abstract
In a continuing effort to develop multitargeted compounds as potential treatment agents against Alzheimer's disease (AD), a certain commercially available flavonoids were evaluated against crystal structure of beta-secretase enzyme using in silico docking studies. In this perspective, flavonoids like apigenin, galangin, gallocatechol, genistein, luteolin, myricetin, and theaflavin were selected. AutoDock 4.2 software was used for the in-silico docking studies which possess the principle of Lamarckian genetic algorithm. In the docking evaluation parameters, binding energy, inhibition constant and intermolecular energy were considered as vital parameters of the ligand against the target. The above-mentioned flavonoids were exhibited binding energy values between -8.69 kcal/mol and -5.01 kcal/mol and inhibition constant values were 427.78 nM to 211.74 µM. Inhibition constant values were coincided with the binding energy. The intermolecular energy of the selected flavonoids was in the range of -9.88 kcal/mol to -6.21 kcal/mol. In the selected flavonoids, galangin showed excellent binding interactions against beta-secretase enzyme because of its structural properties. These molecular docking analyses could lead to the further development of galangin as a potent beta-secretase inhibitor in the management of Alzheimer’s disease.
Keywords: Flavonoids, beta-secretase, binding energy, inhibition constant, intermolecular energy
Cite this Article
Arumugam Madeswaran, Ravi Nivetha, Mohan Bhargav, Menon Lakshmi. In Silico Evaluation of Inhibitory Potential of Some Commercially Available Flavonoids against Beta-Secretase in the Management of Alzhiemer’s Disease. Research & Reviews: A Journal of Drug Design & Discovery. 2019; 6(2): 30–35p.
Keywords
References
Garden GA, La Spada AR. Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration. Cerebellum 2008; 7: 138-49p.
Colton CA. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol. 2009; 4: 399-418p.
Small GW, Rabins PV, Berry PP. Diagnosis and treatment of Alzheimer's disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997; 278: 1363-71p.
Rangasamy SB, Soderstrom K, Bakay RA, et al. Neurotrophic factor therapy for Parkinson’s disease. Prog Brain Res. 2010; 184: 237-64p.
Azza AA, Ahmed HI, El-Samea HAA, et al. The potential effect of caffeine and nicotine co-administration against aluminum induced Alzheimer’s disease in rats. J Alzheimers Dis Parkinsonism 2016; 6: 236-40p.
Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? Exp. Gerontol. 2011; 46: 225-32p.
Thenmozhi AJ, Raja TRW, Manivasagam T, et al. Hesperidin ameliorates cognitive dysfunction, oxidative stress and apoptosis against aluminium chloride induced rat model of Alzheimer's disease. Nutr. Neurosci. 2017; 20(6): 360-8p.
Iqbal K, Alonso AAC, Chen S, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta. 2005; 1739: 198-210p.
Bell KF, Ducatenzeiler A, Ribeiro DS, et al. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol. Aging. 2006; 27: 1644-57p.
Durdagi S, Supuran CT, Strom TA, et al. In silico drug screening approach for the design of magic bullets: a successful example with anti-HIV fullerene derivatized amino acids. J Chem Inf Model. 2009; 49: 1139–43p.
Cosconati S, Forli S, Perryman AL, et al. Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discov. 2010; 5(6): 597-607p.
Asokkumar K, Madeswaran A, George S. Combining in silico and in vitro approaches to evaluate the acetylcholinesterase inhibitory profile of some commercially available flavonoids in the management of Alzheimer’s disease. Int J Biol Macromol. 2017; 95: 199-203p.
Tapas AR, Sakarkar DM, Kakde RB (2008) Flavonoids as nutraceuticals: a review. Trop J Pharm Res. 2008; 7(3): 1089-99p.
Gonzalez R, Ballester I. Effects of flavonoids and other polyphenols on inflammation. Crit Rev Food Sci Nutr. 2011; 51(4): 331-62p.
Nishiumi S, Miyamoto S. Dietary flavonoids as cancer-preventive and therapeutic biofactors. Front Biosci. 2011; 3: 1332-62p.
Morris GM, Huey R, Lindstrom W, et al. AutoDock 4 and AutoDock Tools 4: automated docking with selective receptor flexibility. J Comput Chem. 2009; 19(14):2785-91p.
Madeswaran A, Umamaheswari M, Asokkumar K, et al. Computational drug discovery of potential TAU protein kinase I inhibitors using in silico docking studies. Bangladesh J Pharmacol. 2013; 8: 131-5p.
Morris GM, Goodsell DS, Halliday RS. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998; 19(14): 1639-62p.
Madeswaran A, Asokkumar K. Evaluation of inhibitory affinity potential of the alkaloids against crystal structure of human angiotensin-converting enzyme using Lamarckian genetic algorithm. Orient Pharm Exp Med. 2015; 15(3): 183-9p.
Madeswaran A, Umamaheswari M, Asokkumar K, et al. In Silico docking studies of lipoxygenase inhibitory activity of commercially available flavonoids. Orient Pharm Exp Med. 2012; 12: 157-61p.
Madeswaran A, Umamaheswari M, Asokkumar K, et al. Discovery of potential aldose reductase inhibitors using in silico docking studies. J Comput Methods in Mol Des. 2011; 1: 65-72p.
Zhang S, Kumar K, Jiang X. DOVIS: An implementation for high throughput virtual ening using Autodock. BMC Bioinformatics 2008; 9: 126-8p.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82: 239-59p.
Adlard P, Bush A. Metals and Alzheimer’s disease. J Alzheimers Dis. 2006; 10: 145-63p.
Refbacks
- There are currently no refbacks.
Copyright (c) Research & Reviews: A Journal of Drug Design & Discovery